Eu­ro­pean Com­mis­sion to re­ceive few­er Pfiz­er-BioN­Tech vac­cine dos­es un­der amend­ed con­tract

The Eu­ro­pean Com­mis­sion has made a few changes to its vac­cine con­tract with Pfiz­er and BioN­Tech, re­duc­ing the dose vol­ume while ex­tend­ing the de­liv­ery time­line to cope with “evolv­ing pub­lic health needs.”

The Com­mis­sion pre­vi­ous­ly struck a con­tract in May 2021 for 900 mil­lion dos­es, with the op­tion to pur­chase an­oth­er 900 mil­lion. Of those, 450 mil­lion were ex­pect­ed to be de­liv­ered in 2023, though an amend­ment now calls for few­er dos­es. While nei­ther the Com­mis­sion nor Pfiz­er and BioN­Tech have re­vealed an ex­act amount, an un­named source told Reuters that the amend­ment re­duces the re­main­ing ex­pect­ed dos­es by about a third.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN